(via NewsDirect)
Eight more fibrotic disease patients suffering interstitial lung disease or chronic kidney disease will join part B of the trial, which is examining AD-214’s safety in a standard of care context.
Oldham says the extension is pivotal in AdAlta’s mission to extend its earlier Phase 1 findings, support partnering endeavours and reduce Phase 2’s overall time and cost.
“Our meetings with potential partners at BIO23 in
“We thank all those shareholders who participated in the recent rights offer that contributed towards the funds for Part A of this critical Phase 1 extension.”
The trial’s first healthy volunteer is expected to receive AD-214 in
Contact Details
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source